HomeIndustriesAmgen to Purchase ChemoCentryx in $3.7 Billion Deal

Amgen to Purchase ChemoCentryx in $3.7 Billion Deal

Biopharmaceutical company Amgen Inc has confirmed that it will purchase ChemoCentryx Inc for $3.7 billion. While ChemoCentryx shares are down 34% this year, the announcement saw them double in value to $51.40 before trading commenced. To complete the deal, Amgen will be required to pay $52 per share in cash; a premium of nearly 116% on ChemoCentryx’s stock’s closing price on Wednesday.

By acquiring ChemoCentryx, Amgen will be looking to add the company’s newly approved anti-inflammation treatment to its product portfolio. While Amgen’s arthritis drug, Enbrel, has been a top seller, it now faces stiff competition from new rivals that have recently entered the market. Furthermore, the drug’s patent is set to expire in 2029.

One of the main targets for Amgen was ChemoCentryx’s Tavneos, which was approved late last year. Used to treat a rare form of blood vessel inflammation, Tavneos raked in $5.4 million in sales during the first quarter following its launch.

In addition to Tavneos, there are three drugs that are currently going through early-stage trials that are to be used to treat inflammatory diseases, as well as a cancer drug. Analysts expect the company’s sales to exceed $1 billion by 2027.

European Central Banks Look to Bring Inflation Back to 2% Target

France and Germany's central bank officials have announced their aim to bring inflation back to its 2% target. In a joint interview, Bank of...

Dollar Steadies Near 16-Week Low While Yuan Approaches 15-Year Record Gain

The U.S. dollar stabilized on Friday near a 16-week low when measured against a basket of other currencies including the euro. The currency fell...

Euro Zone Producer Prices Fall, Confirming Analysts’ Inflation Forecasts

The European Union's statistics office Eurostat revealed on Friday that Euro Zone producers' prices fell month-on-month in October by 2.9%. This marks a 30.8%...